FDA working with FTC on switch ads prior to approval -- FTC's Peeler says.
This article was originally published in The Tan Sheet
Executive Summary
FDA WORKING WITH FTC ON Rx-TO-OTC SWITCHES PRIOR TO APPROVAL, Federal Trade Commission Division of Advertising Practices Associate Director Lee Peeler said at a Sept. 7 Food & Drug Law Institute meeting in Washington, D.C. He noted that FDA "has already initiated a series of steps to keep us informed about the advertising issues that are likely to arise after [a] switch" and that the agency is keeping FTC informed as to which switch products are in the pipeline.